Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?

Executive Summary

The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.

Advertisement

Related Content

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing
The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Cempra Goes Back To The Future With New Product/Old Antibiotic Taksta
Solithera’s Prospects Look Grim Following Complete Response Letter
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Advisory Committee Recommendations Could Limit Use Of Solithera
Cempra Details Launch Plans For Solithromycin

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel